Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
Viral gene therapy provides a successful treatment for high-grade, non-muscle invasive bladder cancer resistant to, or recurrent after, treatment with intravesical bacillus Calmette-Guérin (BCG) vaccine. Our therapy provides the first and only way to reliably curtail the progression of superficial, non-muscle invasive cancer into more lethal muscle-invasive cancer.
1 . A method for preventing the progression of non-muscle invasive bladder cancer to muscle-invasive cancer, comprising instilling a virus intra-vesically into the bladder of a human that has been diagnosed with non-muscle invasive bladder cancer, said virus instilled in an amount effective to prevent the progression of non-muscle invasive bladder cancer to muscle-invasive cancer.
2 . The method of claim 1 , where the virus does not replicate in normal healthy bladder cells.
3 . The method of claim 1 , where the virus contains a human interferon gene.
4 . The method of claim 1 , where the human has been diagnosed with high-grade, non-muscle invasive bladder cancer.
5 . The method of claim 1 , where the human has been diagnosed with non-muscle invasive bladder cancer resistant to or recurrent after treatment with bacillus Calmette Guérin.
6 . The method of claim 1 , further comprising instilling a surfactant intra-vesically into the bladder.
7 . The method of claim 1 , where the human has been diagnosed with non-muscle invasive bladder cancer recurrent after resection.
8 . A method for treating high-grade, bacillus Calmette Guérin-unresponsive non-muscle invasive bladder cancer in a human, comprising administering by intravesical instillation, about once every three months, to a human that has been diagnosed with high-grade bacillus Calmette Guérin-unresponsive non-muscle invasive bladder cancer, NODA and about 2.25×10 13 virus particles (vp) of nadofaragene firadenovec.